Recent Company News

• 07:43 PM ET Nov 04, 2025
  

  NICE recommends Viiv's Apretude to prevent HIV-1 in adults and young people who can't have oral PrEP

• 11:46 PM ET Oct 27, 2025
  

  Transcript Intelligence: Shionogi & Co. Q2 Earnings Themes (¥2498.0000, +15)

• 11:46 PM ET Oct 27, 2025
  

  Transcript Intelligence: Shionogi & Co. Q2 Earnings Guidance (¥2498.0000, +15)

• 11:46 PM ET Oct 27, 2025
  

  Transcript Intelligence: Shionogi & Co. Q2 Earnings Q&A (¥2499.0000, +16)

• 02:39 AM ET Oct 27, 2025
  

  StreetAccount Metrics Recap - Shionogi & Co. Q2 Earnings (¥2483.0000, 0)

• 02:37 AM ET Oct 27, 2025
  

  Shionogi & Co. reports Q2 net income attributable ¥44.2B vs FactSet ¥39.72B [3 est, ¥35.56-45.62B] (¥2483.0000, 0)

• 07:08 AM ET Oct 17, 2025
  

  ViiV Healthcare announces 96-week data from PASO DOBLE study of Dovato vs Biktarvy in maintaining virological suppression in HIV-1 pts

• 01:35 AM ET Oct 17, 2025
  

  NICE recommends ViiV Healthcare's cabotegravir (Apretude) as an option for pre-exposure prophylaxis (PrEP)

• 07:07 AM ET Oct 15, 2025
  

  Viiv Healthcare announces data from the Phase I CLARITY open-label, crossover study

• 02:42 AM ET Oct 10, 2025
  

  Japan Tobacco and Shionogi's Torii Pharmaceutical apply for marketing of tapinarof cream 0.5% in Japan for atopic dermatitis in children (¥4904.0000, 0)